EU-India trade deal could derail generic supply chain, MSF warns
This article was originally published in Scrip
Executive Summary
Médecins Sans Frontières (MSF) has warned that the stringent intellectual property enforcement and injunction measures in the proposed EU-India free trade agreement (FTA) could have "chilling" implications for the entire generic medicine supply chain. The international NGO says that the free trade agreement as drafted imposes another piece of legislation, the Anti-Counterfeiting Trade Agreement (ACTA), implementation of which would threaten a range of programmes including those funded by the US President's Emergency Plan for AIDS Relief, UNITAID and the Global Fund, and hurting active pharmaceutical ingredients suppliers from India and possibly China.
You may also be interested in...
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Astellas CStO Pearson: We’re Not Short Of Opportunities To Compensate For LOEs
Astellas’ chief strategy officer, Adam Pearson, talks to Scrip about the company’s launch execution thrust for key therapies ahead of the loss of exclusivity for Xtandi and also deal-making appetite and choices, including the Iveric Bio buyout and walking away from the collaboration with Cartesian Therapeutics.